REMEGEN Surges Over 7% in Early Trading as 11 Original Research Results Set for Major Presentation at ESMO 2025

Deep News

Sep 25

REMEGEN (09995) saw its stock price climb 7.29% in early trading, reaching HK$110.40 with trading volume of HK$359 million.

According to REMEGEN's official announcement, the 2025 European Society for Medical Oncology (ESMO) annual meeting will be held in Berlin, Germany from October 17-21 local time. REMEGEN has successfully secured inclusion of 11 original research results, with multiple clinical research data being disclosed internationally for the first time.

The company will showcase several significant research achievements at the conference. Notably, the RC48-C016 Phase III clinical study of disitamab vedotin combination therapy for first-line urothelial carcinoma has been selected for "Late-Breaking Abstracts (LBA)," demonstrating the important academic value of this research. Additionally, the company will present 10 additional studies covering multiple tumor types and related treatment strategies, including 2 short oral presentations and 8 poster presentations. These cover areas such as urothelial carcinoma, gastric cancer, and gynecological tumors, comprehensively demonstrating REMEGEN's leading capabilities in ADC drug combination therapies.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1156223452"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1156223452\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1156223452?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-25 10:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156223452","market":"other","top_or_hot":-1,"title":"REMEGEN Surges Over 7% in Early Trading as 11 Original Research Results Set for Major Presentation at ESMO 2025","media":"Deep News","content":"<p>REMEGEN (09995) saw its stock price climb 7.29% in early trading, reaching HK$110.40 with trading volume of HK$359 million.</p>\n<p>According to REMEGEN's official announcement, the 2025 European Society for Medical Oncology (ESMO) annual meeting will be held in Berlin, Germany from October 17-21 local time. REMEGEN has successfully secured inclusion of 11 original research results, with multiple clinical research data being disclosed internationally for the first time.</p>\n<p>The company will showcase several significant research achievements at the conference. Notably, the RC48-C016 Phase III clinical study of disitamab vedotin combination therapy for first-line urothelial carcinoma has been selected for \"Late-Breaking Abstracts (LBA),\" demonstrating the important academic value of this research. Additionally, the company will present 10 additional studies covering multiple tumor types and related treatment strategies, including 2 short oral presentations and 8 poster presentations. These cover areas such as urothelial carcinoma, gastric cancer, and gynecological tumors, comprehensively demonstrating REMEGEN's leading capabilities in ADC drug combination therapies.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>REMEGEN Surges Over 7% in Early Trading as 11 Original Research Results Set for Major Presentation at ESMO 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nREMEGEN Surges Over 7% in Early Trading as 11 Original Research Results Set for Major Presentation at ESMO 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2025-09-25 10:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>REMEGEN (09995) saw its stock price climb 7.29% in early trading, reaching HK$110.40 with trading volume of HK$359 million.</p>\n<p>According to REMEGEN's official announcement, the 2025 European Society for Medical Oncology (ESMO) annual meeting will be held in Berlin, Germany from October 17-21 local time. REMEGEN has successfully secured inclusion of 11 original research results, with multiple clinical research data being disclosed internationally for the first time.</p>\n<p>The company will showcase several significant research achievements at the conference. Notably, the RC48-C016 Phase III clinical study of disitamab vedotin combination therapy for first-line urothelial carcinoma has been selected for \"Late-Breaking Abstracts (LBA),\" demonstrating the important academic value of this research. Additionally, the company will present 10 additional studies covering multiple tumor types and related treatment strategies, including 2 short oral presentations and 8 poster presentations. These cover areas such as urothelial carcinoma, gastric cancer, and gynecological tumors, comprehensively demonstrating REMEGEN's leading capabilities in ADC drug combination therapies.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688331","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1156223452","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156223452","pubTimestamp":1758765654,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"REMEGEN (09995) saw its stock price climb 7.29% in early trading, reaching HK$110.40 with trading volume of HK$359 million. According to REMEGEN's official announcement, the 2025 European Society for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688331":"荣昌生物","BK0239":"医药制造","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","BK1161":"生物科技","09995":"荣昌生物","BK1574":"生物医药B类股","BK1583":"高瓴概念"},"translate_title":"REMEGEN早盘飙升逾7%，11项原创研究成果将在ESMO 2025上发表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688331":1,"09995":1},"content_text":"REMEGEN (09995) saw its stock price climb 7.29% in early trading, reaching HK$110.40 with trading volume of HK$359 million.\nAccording to REMEGEN's official announcement, the 2025 European Society for Medical Oncology (ESMO) annual meeting will be held in Berlin, Germany from October 17-21 local time. REMEGEN has successfully secured inclusion of 11 original research results, with multiple clinical research data being disclosed internationally for the first time.\nThe company will showcase several significant research achievements at the conference. Notably, the RC48-C016 Phase III clinical study of disitamab vedotin combination therapy for first-line urothelial carcinoma has been selected for \"Late-Breaking Abstracts (LBA),\" demonstrating the important academic value of this research. Additionally, the company will present 10 additional studies covering multiple tumor types and related treatment strategies, including 2 short oral presentations and 8 poster presentations. These cover areas such as urothelial carcinoma, gastric cancer, and gynecological tumors, comprehensively demonstrating REMEGEN's leading capabilities in ADC drug combination therapies.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}